Full-Time

Quality Systems Auditor

BiVACOR

BiVACOR

51-200 employees

Develops magnetically levitated total artificial heart

Compensation Overview

$126k - $138k/yr

+ Annual bonus

Huntington Beach, CA, USA

In Person

Relocation benefits are not available. Travel of approximately 20–30% may be required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Veeva

Get referred to BiVACOR

See people who can refer or advise you

Requirements
  • A bachelor's degree in Engineering, Life Sciences, Biomedical Engineering, or a related technical discipline is required.
  • At least 10 years of Quality Assurance experience in the medical device industry is required.
  • At least 5 years of direct internal auditing experience against ISO 13485 and/or 21 CFR Part 820 is required.
  • Experience supporting or participating in third-party certification body certification audits for ISO 13485 is required.
  • A thorough working knowledge of ISO 13485:2016 and 21 CFR Part 820 (Quality System Regulation/Quality Management System Regulation) is required.
  • Proficiency with electronic quality management system platforms such as Enlil, ZenQMS, MasterControl, Veeva, or an equivalent platform is required.
  • At least one of the following certifications is required: ISO 13485 Lead Auditor certification from IRCA, Exemplar Global, or an equivalent accredited body; ASQ Certified Quality Auditor; or ASQ Certified Quality Engineer with documented lead auditor training.
Responsibilities
  • Develop and maintain the annual internal audit schedule based on risk, regulatory requirements, and process criticality.
  • Lead and conduct internal audits of Quality Management System processes, including design controls, production and process controls, corrective and preventive action, complaint handling, supplier quality, document and record control, sterilization, and clinical device release.
  • Author audit plans, checklists, and reports in accordance with ISO 13485 and 21 CFR Part 820 requirements.
  • Coordinate with process owners and subject matter experts to schedule and execute audits with minimal disruption to operations.
  • Document nonconformities, observations, and opportunities for improvement with clear objective evidence.
  • Assign and track audit findings through closure, including verification of corrective and preventive action effectiveness.
  • Collaborate with corrective and preventive action owners to ensure root cause analyses are thorough and corrective actions are implemented on schedule.
  • Support third-party certification body audits and surveillance activities, including readiness assessments, escort duties, audit hosting, and certification body interface coordination.
  • Assist with preparation and review of Quality Management System documentation for certification body audit submissions.
  • Provide gap analysis and remediation support against ISO 13485:2016 and 21 CFR Part 820 / Quality System Regulation requirements.
  • Support Investigational Device Exemption compliance activities under 21 CFR Part 812 as needed, including clinical device release audit trail review.
  • Maintain the internal audit program, including audit procedure governance, auditor qualification records, and audit metrics reporting to Quality Assurance leadership.
  • Track and trend audit findings to identify systemic quality issues and improvement opportunities.
  • Support training of staff on internal audit methods and quality system requirements.
  • Travel domestically and internationally as required to support multi-site audits, supplier audits, certification body audits, or clinical site quality oversight activities.
Desired Qualifications
  • Experience with Class III and/or Active Implantable Medical Device development and commercialization.
  • Familiarity with FDA Investigational Device Exemption regulations under 21 CFR Part 812 and clinical device release processes.
  • Working knowledge of ISO 14971 risk management, IEC 62304 software lifecycle, and/or ISO 10993 biocompatibility.
  • Experience auditing sterilization processes such as ethylene oxide or radiation and/or sterile medical device manufacturers.
  • Exposure to Class III Active Implantable Medical Device regulatory submissions, including Premarket Approval and Investigational Device Exemption submissions, or design history file review.
  • Experience in a startup or scale-up medical device environment building Quality Management System infrastructure.
  • Familiarity with supplier quality management and supplier audit execution.
  • Experience pursuing ISO 13485 certification from gap assessment through initial certification.

BiVACOR is a clinical-stage medical device company developing the BiVACOR Total Artificial Heart (TAH) to replace a failing heart. The device is a compact, titanium implant that uses a single magnetically levitated rotor to pump blood to the lungs and the rest of the body, eliminating valves and mechanical bearings to reduce blood damage. It serves as a bridge-to-transplant and aims to become a long-term (permanent) alternative to heart transplantation. BiVACOR operates in the cardiovascular medtech space, pursuing regulatory approval through preclinical and clinical trials, including an FDA Breakthrough Device Designation and an Early Feasibility Study. Its strategy includes expanding from Australia to the US, securing funding, and advancing toward commercialization to address the large unmet need in end-stage heart failure.

Company Size

51-200

Company Stage

Grant

Total Funding

$46.7M

Headquarters

Houston, Texas

Founded

2008

Get referred to BiVACOR

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Five of five U.S. patients bridged to transplant by August 2025 without pump replacement.
  • The 2026 clinical trial recruits four major centers: Duke, Banner, The Christ Hospital, Texas Heart.
  • Australia’s MRFF and NIH grants fund wireless power development and clinical expansion.

What critics are saying

  • The 15-patient expansion increases visibility; one stroke, hemolysis, or infection can halt approvals.
  • Patients need anticoagulation, transplant eligibility, and chest fit; exclusions shrink the addressable pool.
  • No commercial approval exists in 2026; late-stage trial failure would kill BiVACOR’s standalone thesis.

What makes BiVACOR unique

  • BiVACOR’s single-maglev-rotor titanium TAH removes valves, bearings, and mechanical wear points.
  • July 9, 2024 first-in-human implant and five-patient bridge-to-transplant run built credibility.
  • FDA Breakthrough Device and TAP acceptance in 2025 signal unusually close regulator engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Life Insurance

Employee Assistance Program

401(k) Company Match

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-5%

2 year growth

-10%
Wainscot Media
May 30th, 2025
Artificial Heart Receives Breakthrough Device Designation from FDA

May 30, 2025 - BiVACOR, a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), announced that its device has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

TUN
Jul 25th, 2024
Texas Heart Institute Achieves First-Ever BiVACOR Artificial Heart Implantation

The Texas Heart Institute, in collaboration with BiVACOR(R), has made a historic stride in cardiac care with the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH).

Business Wire
Feb 20th, 2024
Bivacor® Receives $13 Million To Support Clinical Trials For The Company’S Total Artificial Heart

GOLD COAST, Australia HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR®, a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements. Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACOR. The $13 million (USD) grant comes from a larger $50 million (AUD) grant from the MRFF to the AHFP to develop and commercialize devices to treat the most common forms of severe heart failure and bring new solutions to underserved patients. The award will support clinical work of the BiVACOR Total Artificial Heart (TAH) and begin development for the integration of wireless power sources for the device

InnovationMap
Jan 8th, 2024
Houston med device company names new CEO

Jim Dillon, a longtime executive in the medical device sector, has been hired to lead BiVACOR and join its board of directors.

The Business Journals
Jan 3rd, 2024
Artificial heart company Bivacor names Jim Dillon new CEO

At the same time, Bivacor also received $3 million in Small Business Innovation Research grant funding from the National Heart, Lung, and Blood Institute at the U.S. National Institute of Health.